P177 | HOME-BASED ADMINISTRATION OF ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PRELIMINARY SINGLE-CENTER EXPERIENCE WITH BISPECIFIC ANTIBODIES

Background: Relapsed/refractory multiple myeloma (RRMM) often requires intensive or innovative therapies that can be logistically challenging, especially for severely immunocompromised patients or for those whose advanced bone disease limits mobility, making frequent hospital visits burdensome. In recent years, bispecific antibodies have emerged as a promising therapeutic class for RRMM. Elranatamab, a bispecific T-cell engager antibody recently approved on the basis of a phase 2 trial, is increasingly becoming part of standard treatment for RRMM patients. Objective: To assess the feasibility and safety of administering the bispecific antibody elranatamab at home within an existing subcutaneous-therapy home-care program. Methods: Elranatamab was introduced at our institution in October 2024. With step-up dosing recommended in an inpatient setting, weekly injections were subsequently given on an outpatient basis. Patients who still had severe functional limitations at discharge were invited to receive treatment at home. Trained home-care nurses delivered the subcutaneous doses, performed on-site safety assessments, and provided supportive and palliative care; physicians conducted regular telehealth or in-person reviews as clinically indicated. Results: Among nine consecutive RRMM patients treated with elranatamab, two met the criteria and consented to home-delivered therapy. No grade ≥3 adverse events occurred, and no treatment interruptions were required. Patient 1 completed three administrations of elranatamab at home before discontinuing because of disease progression. Patient 2 also received three home doses, experienced functional recovery, and subsequently transitioned back to hospital-based care for further cycles. Both patients reported high satisfaction, particularly due to the avoidance of travel burden. Conclusion: These preliminary observations suggest that home administration of elranatamab is feasible, well tolerated, and sustainable in a structured home-care setting. The findings are consistent with experience from other home-based therapies for multiple myeloma and indicate that this approach may be a valuable alternative for patients with temporary functional limitations. Larger studies should investigate cost-effectiveness, long-term outcomes, and patient-reported quality-of-life measures.